InMed Pharmaceuticals (INM) Proxy Filing summary

Executive summary

• A special virtual shareholder meeting is scheduled for June 13, 2025, to approve the potential issuance of 20% or more of outstanding common shares under a Standby Equity Purchase Agreement (SEPA) with Yorkville, as required by Nasdaq rules.

• The SEPA allows the company to sell up to $10 million in common shares to Yorkville over 36 months, with $2.46 million already sold and $7.54 million remaining.

• Shareholder approval is sought to issue shares in excess of the 20% cap, which would provide flexible access to capital for general corporate purposes.

• Failure to approve may limit funding options and force the company to seek less favorable alternatives.

Voting matters and shareholder proposals

• The main proposal is to approve the issuance of 20% or more of the company’s shares under the SEPA, as required by Nasdaq Listing Rules 5635(d) and 5635(b).

• Shareholders can vote by proxy online, by mail, or by fax, and may appoint a proxyholder of their choice.

• The board unanimously recommends voting in favor of the proposal.

Board of directors and corporate governance

• No director, executive officer, or nominee has a material interest in the matters to be acted upon at the meeting.

• The board has approved the contents and mailing of the information circular.